The links on this page are not affiliated with Mitsubishi Tanabe Pharma America, Inc. (MTPA). Links to sites outside of MTPA are provided as a resource to the viewer. MTPA accepts no responsibility for the content of linked sites. Some links may direct to third-party websites that require a subscription to access publications.
-
Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis
—Brooks BR, Berry JD, Ciepielewska M, et al. Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis. eClinicalMedicine. 2022;52:101590. doi: 10.1016/j.eclinm.2022.101590.

View article
-
Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19)
—Shefner J, Heiman‐Patterson T, Pioro EP, et al. Long‐term edaravone efficacy in amyotrophic lateral sclerosis: post‐hoc analyses of Study 19 (MCI186‐19). Muscle Nerve. 2020;61(2):218-221. doi: 10.1002/mus.26740.

View article
-
Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]
—Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, et al. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PloS One. 2022;17(6):e0258614. doi: 10.1371/journal.pone.0258614.

View reference
-
Analysis of the US safety data for edaravone (Radicava®) from the third year after launch
—Genge A, Brooks BR, Oskarsson B, et al. Analysis of the US safety data for edaravone (Radicava®) from the third year after launch. Drugs R D. 2022;22(3):205-211. doi: 10.1007/s40268-022-00391-6.

View reference
-
Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19
—Brooks BR, Pioro EP, Katz J, et al. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19. Muscle Nerve. 2022;65(2):180-186. doi: 10.1002/mus.27467.

View reference
-
Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study
—Berry JD, Bedlack R, Mathews D, et al. Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(1-2):147-150. doi: 10.1080/21678421.2020.1804939.

View reference
-
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool
—Brooks BR, Pioro EP, Beaulieu D, et al. Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1-2):49-57. doi: 10.1080/21678421.2021.1927102.

View article
-
Clinical staging in amyotrophic lateral sclerosis: analysis of edaravone Study 19
—Al-Chalabi A, Chiò A, Merrill C, et al. Clinical staging in amyotrophic lateral sclerosis: analysis of edaravone Study 19. J Neurol Neurosurg Psychiatry. 2021;92(2):165-171. doi: 10.1136/jnnp-2020-323271.

View article
-
Treatment persistence among amyotrophic lateral sclerosis patients receiving intravenous edaravone: results from a national infusion center
—Hagan M, Ciepielewska M, Harrison A, et al. Treatment persistence among amyotrophic lateral sclerosis patients receiving intravenous edaravone: results from a national infusion center. Poster presented at virtual 31st International Symposium on ALS/MND; December 9-11, 2020.
View poster
-
Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis
—Palumbo JM, Hubble J, Apple S, et al. Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):421-431. doi: 10.1080/21678421.2019.1599955.

View article
-
A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
—The Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):11-19. doi: 10.1080/21678421.2017.1363780.

View article
-
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
—The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512. doi: 1016/S1474-4422(17)30115-1.

View article
The studies referenced herein are provided for general information only and are not intended as statements about the safety or efficacy of any product.